TP53 and hepatocellular carcinoma: Finally, we demonstrated that the glycolytic subtypes, which were associated with TP53 mutations, may be more likely to benefit from KDT, and further validated the predictive value of the metabolic subtypes in KDT using HCC xenograft models.